Ok Biotech Co Ltd Total Assets
Ok Biotech Co Ltd total assets. Based on the latest financial reports, Ok Biotech Co Ltd (4155) holds total assets worth NT$3.99 Billion TWD (≈ $125.82 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Ok Biotech Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Ok Biotech Co Ltd (2009–2025)
Total assets of Ok Biotech Co Ltd from 2009 to 2025. This chart illustrates how Ok Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Ok Biotech Co Ltd stock price today for real-time trading data and today's change.
Ok Biotech Co Ltd - Asset Composition Analysis
Ok Biotech Co Ltd Total Assets Breakdown (December 2025)
Ok Biotech Co Ltd total assets breakdown as of December 2025. Ok Biotech Co Ltd's total assets of NT$3.99 Billion consist of 32.5% current assets and 67.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.2% |
| Accounts Receivable | NT$409.84 Million | 10.7% |
| Inventory | NT$456.00 Million | 11.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$111.56 Million | 2.9% |
| Goodwill | NT$353.52 Million | 9.2% |
Asset Composition Trend (2009–2025)
This chart illustrates how Ok Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Ok Biotech Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ok Biotech Co Ltd's current assets represent 32.5% of total assets in 2025, a decrease from 79.1% in 2009.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2025, down from 15.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 11.9% of total assets.
Ok Biotech Co Ltd Competitors by Total Assets
Key competitors of Ok Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Ok Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.40 | 1.81 | 2.17 |
| Quick Ratio | 1.62 | 1.09 | 1.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$801.56 Million | NT$555.36 Million | NT$777.18 Million |
Ok Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ok Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | NT$3.85 Billion |
| Market Capitalization | $60.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ok Biotech Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ok Biotech Co Ltd's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ok Biotech Co Ltd (2009–2025)
The table below shows the annual total assets of Ok Biotech Co Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.85 Billion ≈ $121.28 Million |
+4.17% |
| 2024-12-31 | NT$3.70 Billion ≈ $116.42 Million |
+20.47% |
| 2023-12-31 | NT$3.07 Billion ≈ $96.64 Million |
+0.20% |
| 2022-12-31 | NT$3.06 Billion ≈ $96.44 Million |
+8.83% |
| 2021-12-31 | NT$2.81 Billion ≈ $88.62 Million |
+10.95% |
| 2020-12-31 | NT$2.54 Billion ≈ $79.87 Million |
+14.17% |
| 2019-12-31 | NT$2.22 Billion ≈ $69.96 Million |
+19.98% |
| 2018-12-31 | NT$1.85 Billion ≈ $58.31 Million |
-1.77% |
| 2017-12-31 | NT$1.88 Billion ≈ $59.36 Million |
+25.99% |
| 2016-12-31 | NT$1.50 Billion ≈ $47.11 Million |
+3.45% |
| 2015-12-31 | NT$1.45 Billion ≈ $45.54 Million |
+2.48% |
| 2014-12-31 | NT$1.41 Billion ≈ $44.44 Million |
-3.16% |
| 2013-12-31 | NT$1.46 Billion ≈ $45.89 Million |
+87.29% |
| 2012-12-31 | NT$777.74 Million ≈ $24.50 Million |
+59.89% |
| 2011-12-31 | NT$486.42 Million ≈ $15.32 Million |
+49.49% |
| 2010-12-31 | NT$325.39 Million ≈ $10.25 Million |
+58.98% |
| 2009-12-31 | NT$204.67 Million ≈ $6.45 Million |
-- |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-f… Read more